IOVA · Iovance Biotherapeutics, Inc.
$14.73
-0.09 (-0.61%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$4.98B
Shares
452.97M
Volume · Sep 30
29.34M
Avg daily vol (3M)
17.86M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.82
Open$14.65
Day$14.10–15.11
52W close$1.81–14.82
Avg vol 30d17.8M
Short int87.1M · 19.2% float · 7.4d
Short vol43%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$324.97M
Trailing 12 months
Net income (TTM)
−$289.52M
Trailing 12 months
Revenue growth YoY
+65.7%
Year over year
Operating margin
-92.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$297.67M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.6%
Year over year · more shares
Price change (1Y)
+548.0%
Trailing year
Short interest
19.2%
Latest settlement · 7.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+221%
above
Price vs 50-day avg
+87%
above
RSI (14)
87
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+79%
trailing
6-month return
+270%
trailing
YTD return
+443%
this year
Relative strength
+257%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +44 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.23% of float · ▼ -1.1% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
294 holders — mid 3-yr range
Squeeze score
100
high risk · 0–100
Fundamentals
EPS growth
+15%
Y/Y
Free cash flow
$-336.2M
Quant / Vol
risk profile
Volatility
105%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total product revenue
· FY26
Initiated
$350M – $370M
prior FY $263.5M
midpoint +36.6% Y/Y
Prior guidance
period ended
· from the 8-K filed May 7, 2026
Total product revenue
· 2Q26
$86M – $88M
Guided vs delivered
· last 1 settled
Total product revenue
2Q26
guided $86M – $88M
$99.31M
Beat +14.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+221%
Bullish
Price vs 50-day avg
+87%
Bullish
RSI (14)
87
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +44 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
19.23% of float · ▼ -1.1% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
294 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $15 · 100%
Range high $15
vs 200-day avg +221%
vs 50-day avg +87%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Amtagvi manufacturing turnaround time | 31 | Q2 2026 | — |
| Authorized treatment center (ATC) network | 95 | Q2 2026 | — |
| Cash position | $304M | As of June 30, 2026 | — |
| Gross margin | 56% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IOVA
this stock
Iovance Biotherapeutics, Inc.
|
$4.98B | +442.9% | +60.6% | — | 19.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IOVA | +45.4% | +79.0% | +269.6% | +81.4% | +442.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +46.1% | +78.9% | +257.4% | +82.0% | +431.0% |